Lataa...
Considerations for using potential surrogate endpoints in cancer screening trials
The requirement of large-scale expensive cancer screening trials spanning decades creates considerable barriers to the development, commercialisation, and implementation of novel screening tests. One way to address these problems is to use surrogate endpoints for the ultimate endpoint of interest, c...
Tallennettuna:
| Julkaisussa: | Lancet Oncol |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2024
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7616115/ https://ncbi.nlm.nih.gov/pubmed/38697164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(24)00015-9 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|